Skip to main content

Higher baseline heart rate variability in CCHS patients with progestin-associated recovery of hypercapnic ventilatory response


After a fortuitous observation of two cases of chemosensitivity recovery in women with congenital central hypoventilation syndrome (CCHS) who took desogestrel, we aimed to evaluate the ventilatory response to hypercapnia of five CCHS patients with or without treatment consisting of desogestrel (DESO) or levonorgestrel (LEVO). Only two patients became responsive to hypercapnia under treatment, according to their basal vagal heart rate variability. These results suggest that heart rate variability may be promising tool to discriminate patients susceptible to become responsive to hypercapnia under DESO-LEVO treatment.

Clinical Trials Identifier NCT01243697


In humans, heterozygous expansions of a normal 20-alanine repeat sequence in the PHOX2B gene (PARM mutation) cause an array of phenotypic defects. Affected patients typically suffer from central hypoventilation (hence the congenital central hypoventilation syndrome denomination, CCHS) that requires ventilatory assistance during sleep and is characterized by reduced or absent CO2-chemosensitivity [1]. Studies point at a developmental defect of PHOX2B-expressing CO2/H + sensitive neurons in the retrotrapezoid nucleus as the source of the chemosensitivity defect [2]. Among various vegetative anomalies, CCHS patients also exhibit cardiovascular autonomic dysregulation [3]. Building on the serendipitous description of two cases of CO2-chemosensitivity recovery in CCHS women receiving desogestrel, a progestin contraceptive [4], we conducted a clinical trial to examine the effects of desogestrel treatment on the ventilatory response to CO2 (RESPIRONDINE study, NCT01243697). We also examined the cardiac autonomic balance, keeping in mind that acute hypercapnia is associated with an increase in vagal tone in healthy subjects [5]. A preliminary form of this work was published as an abstract for a national congress, Les Journées de Recherche Respiratoire 2014 (Rev Mal Respir 2015: 32 (3), 338).


Inclusion criteria were: CCHS pubescent females, carrying a PARM mutation and without contraindication to desogestrel treatment. Non-inclusion criteria were: contraindication to desogestrel treatment, estrogen-progestogen therapy for another purpose than contraception, pregnancy, non PARM mutation. Patients not previously under oral contraception (arm#1) were studied at baseline (“without treatment”), prescribed desogestrel 75 μg/day for 3 weeks to 3 months, and studied again (“with treatment”). Patients previously taking an oral contraception not comprising desogestrel nor levornorgestrel (arm#2) were asked to interrupt it for 4 months, after which they followed the same procedure as in arm#1. Patients previously taking a desogestrel or levonorgestrel based contraception (arm#3) were studied at baseline (“with treatment”) and then after 1 to 4 months of treatment discontinuation (“without treatment”).

The response to CO2 was studied using Read’s closed circuit rebreathing technique [6], starting with a 7%CO2—93%O2 gas mixture (Hyp’Air Compact +, Medisoft, Sorinnes-Dinant, Belgium), and characterized in terms of the slope of the minute ventilation (V’E)—end-expiratory end tidal CO2 partial pressure (PETCO2) expressed in L.min−1.mmHg−1. CO2 sensitivity was also assessed by the change in V’E (∆V’E) between steady-state air breathing (normoxia) and exposure to hyperoxic hypercapnia (5% CO2—95% O2). V’E was calculated as the mean V’E between the 5th and the 10th minute of gas mixture exposure. Electrocardiographic recordings (EKG) collected during steady-state air breathing and 5%CO2 hypercapnia were used to characterize autonomic cardiac regulation through an analysis of heart rate variability (HRV) using Poincaré plots [7], a type of recurrence plot where one takes a sequence of intervals and plots each interval against the following interval (R-R interval in the case cardiac studies). The dispersion across the line of identity (the “plot width”, SD1) reflects short-term variability (a marker of the vagal activity in the case of HRV). The length of the scattergram along the line of identity reflects long-term variability (SD2, a marker of the summation of sympathetic and parasympathetic activities in the case of HRV). The SD2/SD1 ratio is a marker of sympathetic activity [8].

Power spectra from R-R intervals were obtained by Fourier transformation (size 128, Hanning window, giving results with frequencies from 0 to 0.5 Hz and a final frequency resolution of 0.007 Hz). Low- (LF) and high-frequency (HF) powers were within the ranges of 0.04–0.15 Hz and 0.15–0.40 Hz, respectively [9]. LF (a reflection of the summation of sympathetic and parasympathetic activities [10, 11]) and HF (a marker of the vagal tone [12, 13]) powers (ms2/Hz) were calculated. The ratio between LF and HF bands (LF/HF, a marker of the sympathetic activity) were determined [14].


Five patients were included in the study (arm#1: #1: age 31, 20/26 alanine expansion; #2: age 30, 20/29. Arm#2: #3: age 24, 20/27. Arm#3: #4: age 22, 20/25; #5: age 24, 20–26). According to the CO2 rebreathing data, patients #1, #2 and #3 kept a near-abolished ventilatory response in the “with treatment” condition compared to the “without treatment” (0.26 vs 0.01 L.min−1.mmHg−1, 0.18 vs 0.18 L.min−1.mmHg−1, and 0.22 vs 0.08 L.min−1.mmHg−1 respectively). A steady-state response to 5% CO2 (∆V’E) was present but low and not clearly sensitive to treatment (∆V’E: 0.57 vs 0.89 L.min−1, 1.35 vs 1.63 L.min−1 and 2.8 vs 1.5 L.min−1 with and without treatment, respectively). Patients #4 and #5 had a normal ventilatory response to rebreathing (1.76 and 2.55 L.min−1.mmHg−1, respectively) in the "with treatment condition". Of note, patient #4 was taking desogestrel for four years and patient #5 a combination of levonorgestrel and ethinylestradiol for almost three years at the time of inclusion (arm#3). Both of them had no ventilatory response to CO2 before taking oral contraception. The recovery of a response in patient #4 with desogestrel had previously been published [4]. In the current study, their CO2 response were still normal but lower in the “without treatment” condition, namely after 1 to 4 month washout (1.07 and 1.94 L.min−1.mmHg−1, respectively). In the steady state condition, ∆V’E was 2.42 L.min−1 for patient #4 with treatment and not available for technical reasons without treatment. For patient #5, ∆V’E was 4.27 L.min−1 and 0.56 L.min−1 with and without treatment respectively.

Poincaré return maps (Fig. 1) in steady-state conditions indicated that, during Normoxia, Patients #1, #2 and #3 had a reduced HRV as compared to Patients #4 and #5, with lower SD1 and HF and higher SD2/SD1 and LF/HF, indicating an alteration of the autonomic nervous system in favour of an increase in sympathetic activity and reduced vagal function. This was true in the “without treatment” and the “with treatment” conditions (Fig. 2). During steady-state 5% hypercapnia, no apparent changes were seen in Patients #1, #2 and #3 whereas SD1 increased in Patients #4 and #5, both without treatment” and “with treatment” (Fig. 2).

Fig. 1
figure 1

Qualitative beat-to-beat analysis of RR-intervals during steady state air breathing (normoxia) using Poincaré analysis and Frequential analysis. Note the higher dispersion of points in Poincare ellipses in Patients 4 and 5 (responsive to Rebreathing) compared to the others (non-responsive to Rebreathing), indicating higher heart rate variability in these patients

Fig. 2
figure 2

Poincaré indexes and Frequential parameters during and steady-state air breathing (normoxia) and CO2 challenge. Increases in vagal SD1 during hypercapnia were seen in Group 1 patients only, with or without (washout) treatment


In a very limited number of patients, this exploratory analysis may suggest that CCHS patients with PARM mutation who recover a ventilatory response to CO2 when prescribed desogestrel alone or levonorgestrel combined with ethinylestradiol had higher cardiac autonomic balance and some degree of cardiac response to CO2 at rest.

The current results also suggest that: (i) levonorgestrel, possibly combined with ethinylestradiol, may allow some patients to recover a ventilatory response to hypercapnia, as it was already suggested for desogestrel [4], (ii) all patients do not respond to these drugs and (iii) when present, recovery lasts several months after stopping the treatment. The two women of this study with a recovery of a ventilatory response to hypercapnia took the progestin for three to four years. However, one of the patients whose case was previously published [4] showed a response after only three weeks of treatment. It is therefore difficult to speculate on a possible role of treatment duration in the recovery of the ventilatory response to CO2.

Etonogestrel, a desogestrel precursor, has been shown to enhance the respiratory response to metabolic acidosis in newborn rats [15]. In addition, desogestrel activates c-FOS expression in raphe nuclei serotonergic cells [16]. Keeping in mind that serotonin released from the raphe nuclei to the nucleus tractus solitarius (NTS) facilitates vagal responses [17], and that Phox2B neurones present in the NTS may participate to central chemosensitivity [18], it could be postulated that the effects of desogestrel or levonorgestrel on hypercapnic responses and cardiac response to CO2 in Patients #4 and #5 depend on a preserved NTS serotonin responsiveness.

We acknowledge that further experiments with a higher number of patients are needed. Meanwhile, we submit that HRV analyses could help identify progestin-responder among CCHS patients.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author and Pr Christian Straus on reasonable request.


  1. Amiel J, Laudier B, Attié-Bitach T, et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet. 2003;33(4):459–61.

    Article  CAS  PubMed  Google Scholar 

  2. Ramanantsoa N, Gallego J. Congenital central hypoventilation syndrome. Respir Physiol Neurobiol. 2013;189(2):272–9.

    Article  CAS  PubMed  Google Scholar 

  3. Trang H, Girard A, Laude D, Elghozi JL. Short-term blood pressure and heart rate variability in congenital central hypoventilation syndrome (Ondine’s curse). Clin Sci Lond Engl 1979. 2005;108(3):225–30.

    Article  Google Scholar 

  4. Straus C, Trang H, Becquemin MH, Touraine P, Similowski T. Chemosensitivity recovery in Ondine’s curse syndrome under treatment with desogestrel. Respir Physiol Neurobiol. 2010;171(2):171–4.

    Article  CAS  PubMed  Google Scholar 

  5. Martino PF, Miller DP, Miller JR, et al. Cardiorespiratory response to moderate hypercapnia in female college students expressing behaviorally inhibited temperament. Front Neurosci. 2020;14: 588813.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Read DC. A clinical method for assessing the ventilatory response to carbon dioxide. Australas Ann Med. 1967;16(1):20–32.

    Article  CAS  PubMed  Google Scholar 

  7. Kamen PW, Krum H, Tonkin AM. Poincaré plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans. Clin Sci Lond Engl 1979. 1996;91(2):201–8.

    CAS  Google Scholar 

  8. Guzik P, Piskorski J, Krauze T, et al. Correlations between the Poincaré plot and conventional heart rate variability parameters assessed during paced breathing. J Physiol Sci. 2007;57(1):63–71.

    Article  PubMed  Google Scholar 

  9. Task Force. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996;17(3):354–381.

  10. Pagani M, Lombardi F, Guzzetti S, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res. 1986;59(2):178–93.

    Article  CAS  PubMed  Google Scholar 

  11. Berntson GG, Bigger JT, Eckberg DL, et al. Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology. 1997;34(6):623–48.

    Article  CAS  PubMed  Google Scholar 

  12. Eckberg DL. Human sinus arrhythmia as an index of vagal cardiac outflow. J Appl Physiol. 1983;54(4):961–6.

    Article  CAS  PubMed  Google Scholar 

  13. Pomeranz B, Macaulay RJ, Caudill MA, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol. 1985;248(1 Pt 2):H151-153.

    CAS  PubMed  Google Scholar 

  14. Friedman BH. An autonomic flexibility-neurovisceral integration model of anxiety and cardiac vagal tone. Biol Psychol. 2007;74(2):185–99.

    Article  PubMed  Google Scholar 

  15. Loiseau C, Osinski D, Joubert F, Straus C, Similowski T, Bodineau L. The progestin etonogestrel enhances the respiratory response to metabolic acidosis in newborn rats. Evidence for a mechanism involving supramedullary structures. Neurosci Lett. 2014;567:63–7.

    Article  CAS  PubMed  Google Scholar 

  16. Joubert F, Perrin-Terrin AS, Verkaeren E, et al. Desogestrel enhances ventilation in ondine patients: animal data involving serotoninergic systems. Neuropharmacology. 2016;107:339–50.

    Article  CAS  PubMed  Google Scholar 

  17. Sévoz-Couche C, Comet MA, Bernard JF, Hamon M, Laguzzi R. Cardiac baroreflex facilitation evoked by hypothalamus and prefrontal cortex stimulation: role of the nucleus tractus solitarius 5-HT2A receptors. Am J Physiol Regul Integr Comp Physiol. 2006;291(4):R1007-1015.

    Article  CAS  PubMed  Google Scholar 

  18. Fu C, Xue J, Wang R, et al. Chemosensitive Phox2b-expressing neurons are crucial for hypercapnic ventilatory response in the nucleus tractus solitarius. J Physiol. 2017;595(14):4973–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


The authors thank the Centre d’Investigation Clinique CIC-1901 module Paris-Est for hosting the study. The study was funded by Direction de la Recherche Clinique et de l’Innovation Assistance Publique—Hôpitaux de Paris, Paris, France. The Direction de la Recherche Clinique et de l’Innovation, Assistance Publique—Hôpitaux de Paris, Paris, France also served as the study legal sponsor.


The study sponsor was the Direction de la Recherche Clinique et de l’Innovation (DRCI) of Assistance Publique-Hôpitaux de Paris (AP-HP).

Author information

Authors and Affiliations



Conception and design of the work: CS-C, TS, CS. Acquisition and analysis of data: CS-C, BC, CS. Interpretation of data: CS-C, TS, CS. Drafting the work or revising it critically for important intellectual content: All authors. Final approval of the version to be published: All authors. Agreement to be accountable for all aspects of the work: All authors.

Corresponding author

Correspondence to Caroline Sevoz-Couche.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the appropriate regulatory and ethical bodies (CPP Ile-de-France VI, CPP/60-11—EudraCT: 2011-000989-35, September 2nd, 2011). The patients provided written informed consent to participate.

Competing interests

Dr. T. SIMILOWSKI reports personal fees for consulting and teaching activities from AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc., OSO-AI, TEVA France, Vitalaire, all outside the present study. He is a stock shareholder of startups Hephaï and Austral Dx, which bear no relationship with the present study. He is listed as inventor on several patents, granted or pending, without relationship with the present study. Dr M. PATOUT reports grants or contracts from Fisher & Paykel, Resmed and Asten Santé, and personal fees for consulting and teaching activities from Philips Respironics, Resmed, Asten Santé, GSK, Vitalaire, SOS Oxygene, Chiesi, Elivie, Breas, Bastide, Air Liquide Medical, Antadir, Jazz Pharmaceuticals, Loewenstein, all outside the present study. He also reports support for attending meetings and/or travel from Asten Santé et Vitalaire, and participates on Data Safety Monitoring Board or Advisory Board of Philips Respironics, Resmed, Asten Santé, as well as receipt of equipment, materials, drugs or other services form Philips Respironics, Resmed and Fisher & Paykel, all without relationship with the present study. He is a stock shareholder of Kernel Biomedical which bears no relationship with the present study. Dr C. STRAUS reports grant and support from Centre Hospitalier de Lille and CARMAT, without relationship with the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sevoz-Couche, C., Patout, M., Charbit, B. et al. Higher baseline heart rate variability in CCHS patients with progestin-associated recovery of hypercapnic ventilatory response. Respir Res 25, 87 (2024).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: